Programme Thesis
The i-Lab Competition provides equity-free grants up to €600,000 to early-stage deep-tech projects in France that have validated proof-of-concept and a clear path to commercialization. It exists to de-risk and accelerate breakthrough innovations—especially in AI, health tech, and sustainability—by funding the transition from research to market-ready product.
Selection Criteria
- Technological innovation and breakthrough potential (must be substantial, not incremental)
- Proof-of-concept validation and technical feasibility
- Clear commercialization pathway and economic impact
- Team expertise and ability to execute (founder background, scientific/technical credentials)
- Alignment with key sectors: AI, health tech, sustainable tech
- Measurable project milestones and realistic timeline (max 3 years)
- Scalability and societal challenge relevance (e.g., drug resistance, climate change)
Past Winners / Cohort Profiles
Past winners are typically deep-tech startups with strong academic or research roots, often spun out from French labs or universities. Archetypes include AI-driven drug discovery platforms, biotech tools, and sustainable tech ventures. Named examples are not provided on the page, but the program historically favors projects with a clear innovation edge and a founder with a technical or scientific PhD or equivalent track record.
Ideal Candidate Fingerprint
The ideal applicant is a deep-tech startup with a validated proof-of-concept, a strong scientific or engineering founder (often PhD-level), and a technology that addresses a major societal challenge (e.g., health, environment). The project must show both high innovation and a credible route to market, with measurable milestones and a clear economic impact within three years.
Recommended Framing
Eniola should lead with her unique dual expertise as a pharmacist-turned-ML engineer, positioning herself as the ideal founder to bridge biology and AI. Emphasize that her technology—ESM-2 delta-embeddings + ECFP4 fingerprints—achieves 100% mutation coverage versus 17.6% for structure-dependent tools, solving a critical bottleneck in drug resistance prediction. Frame the current AUROC of 0.634 as a baseline that will be improved to ≥0.70 via fine-tuning on SKEMPI 3K, aligning with the program's demand for measurable milestones and societal impact in health tech.
Watch Out
The venture is not yet incorporated in France, which may be an eligibility requirement (i-Lab typically requires a French-registered company or a commitment to incorporate). The AUROC of 0.634 is below the published SOTA (0.70), so the application must convincingly show a clear path to improvement. Solo founder status may be a weakness; the program may favor teams with complementary expertise.